Patents
Literature
10 results about "Protein L" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Protein L was first isolated from the surface of bacterial species Peptostreptococcus magnus and was found to bind immunoglobulins through L chain interaction, from which the name was suggested. It consists of 719 amino acid residues. The molecular weight of Protein L purified from the cell walls of Peptostreptoccus magnus was first estimated as 95kD by SDS-PAGE in the presence of reducing agent 2-mercaptoethanol, while the molecular weight was determined to 76kD by gel chromotography in the presence of 6 M guanidine HCl. Protein L does not contain any interchain disulfide loops, nor does it consist of disulfide-linked subunits. It is an acidic molecule with a pI of 4.0. Unlike Protein A and Protein G, which bind to the Fc region of immunoglobulins (antibodies), Protein L binds antibodies through light chain interactions. Since no part of the heavy chain is involved in the binding interaction, Protein L binds a wider range of antibody classes than Protein A or G. Protein L binds to representatives of all antibody classes, including IgG, IgM, IgA, IgE and IgD. Single chain variable fragments (scFv) and Fab fragments also bind to Protein L.
Protein l-binding polypeptide and use thereof
The purpose of the present invention is to provide a polypeptide capable of binding to protein L. Provided is a protein L-binding polypeptide comprising amino acid sequence 1, which is L1 sequence (such as the amino acid sequence represented by SEQ ID NO: 1) - antigen recognition sequence 1 - L2 sequence (such as the amino acid sequence represented by SEQ ID NO: 2) - antigen recognition sequence 2 - L3 sequence (such as the amino acid sequence represented by SEQ ID NO: 3) - antigen recognition sequence 3 - L4 sequence (such as the amino acid sequence represented by SEQ ID NO: 4).
Owner:NAT UNIV KYOTO INST OF TECH
Attenuated variant of the rift valley fever virus, composition comprising same, and uses thereof
ActiveUS12584116B2SsRNA viruses negative-senseViral antigen ingredientsPharmaceutical drugVeterinary Drugs
The invention relates to an attenuated variant of the Rift Valley Fever Virus (RVFV) with mutations in the amino acid sequence coded by segments L, M and S of RVFV RNA; a pharmaceutical or veterinary composition comprising same; an attenuated RVFV variant for use in the prevention of Rift Valley Fever, and a vaccine against Rift Valley Fever comprising the attenuated RVFV variant. Attenuated RVFV variants with the mutations Gly924Ser and Ala303Thr in protein L, and the Pro82Leu substitution in protein NSs, are also included.
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Recombinant protein l protein with improved alkali resistance and use thereof
PCT designated stageWO2026057090A1Microorganism based processesPeptide preparation methodsEngineeringBiochemistry
The present application relates to the technical field of protein engineering, and specifically provides a recombinant Protein L protein with improved alkali resistance and use thereof. The recombinant Protein L protein of the present application has higher stability under alkaline conditions while maintaining high binding ability to immunoglobulins, thereby providing a more efficient and economical method for isolating immunoglobulins.
Owner:ACROBIOSYSTEMS AG
PHOTOREACTIVE ANTIBODY-BINDING DOMAIN FOR SITE-SPECIFIC MODIFICATION OF THE ANTIGEN BINDING FRAGMENT (Fab) OF IgG AND IgM
PendingUS20260043807A1Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenDisease
Provided is an adapter comprising an antibody binding domain (AbBD) that specifically binds and crosslinks to an immunoglobulin Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement / modification at A28, G32, Q35, S36, N46, G49, E50, K53 or L54 of SEQ ID NO: 1 or combinations thereof, and where the AbBD is photoreactive. Also provided is an adapter comprising an AbBD that specifically binds and crosslinks to an IgG Fab region and / or to an immunoglobulin M (IgM) Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement / modification at A28, E50, or L54 of SEQ ID NO: 1 or combinations thereof, where the AbBD is photoreactive. Provided is an adapter comprising an AbBD that specifically binds and crosslinks to an IgG Fab region, where the AbBD is a variant of a Protein L C* domain and has an amino acid replacement / modification at G22 or T46 of SEQ ID NO: 2 or a combination thereof, wherein the AbBD is photo-reactive. Methods for using the AbBD for imaging, diagnosing and / or treating a disease are provided.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
Method for purifying eimeracil antibody
PendingCN121930354AImmunoglobulins against blood coagulation factorsHybrid immunoglobulinsAntiendomysial antibodiesBiochemistry
The invention relates to a purification method of an eimeracil antibody. According to the method, through protein L affinity chromatography, the eimeracil antibody is purified by utilizing the binding force difference between the target antibody / homopolymer and the filler, and compared with protein A affinity chromatography, the eimeracil antibody can be more effectively purified. Elution is carried out through a proper elution pH value, the homologous polymer can be further reduced, the purity of the eimeracil antibody can be effectively improved, the content of the homologous polymer can be reduced, and the method is simple in process and easy to operate.
Owner:QILU PHARMA CO LTD
Protein l-binding polypeptide and use thereof
To provide a polypeptide capable of binding to protein L.SOLUTION: A protein L-binding polypeptide comprising an amino acid sequence 1, that is, L1 sequence-antigen recognition sequence 1-A L2 sequence-antigen recognition sequence 2-A L3 sequence-antigen recognition sequence 3-A L4 sequence. The L1 sequence, L2 sequence, L3 sequence, and L4 sequence are each a specific amino acid sequence. The antigen-recognizing sequences 1, 2, and 3 may be an amino acid sequence encoding the light chain CDR1, an amino acid sequence encoding the light chain CDR2, and an amino acid sequence encoding the light chain CDR3, respectively, or an amino acid sequence encoding the heavy chain CDR1, an amino acid sequence encoding the heavy chain CDR2, and an amino acid sequence encoding the heavy chain CDR3, respectively.SELECTED DRAWING: None
Owner:NAT UNIV KYOTO INST OF TECH
Artificial antigen presenting cells comprising protein L for expanding immune cells for immunotherapy
Disclosed herein are methods of expanding immune cells for immunotherapy and / or increasing the purity of a population of CAR T cells using artificial antigen presenting cells (aAPCs) having on their surface Protein L. The disclosed aAPCs can also secrete antibodies that bind molecules of the T cell inhibitory pathway. For example, anti-CD3 scFv on the surface of the aAPCs can bind and activate T cells, while anti-CD28 scFv and 4-1BBL on the surface of the aAPCs can provide dual co-stimulation for the T cells resulting in decreased levels of the markers CD25, TIM3, LAG3, and PD1. For example, blocking PD1 / PDL1 ligation can limit suppression that is mediated by the tumor microenvironment. This is a less costly and more efficient alternative to peripheral blood mononuclear cells (PBMCs) and cytokine treatments that result in better quality T cell for adoptive transfer back into patients.
Owner:H LEE MOFFITT CANCER CENT & RES
Purification method of fasuximab
PendingCN122060072Ahigh purityHybrid immunoglobulinsImmunoglobulins against growth factorsBiochemistryPharmacology
The invention relates to a purification method of fasuximab. According to the method, through protein L affinity chromatography, the fasuximab is purified by utilizing the binding force difference between a target antibody / polymer impurity and a filler, and compared with a nano antibody ligand affinity medium, the fasuximab can be more effectively purified. In addition, compared with conventional low-pH elution, the antibody and the polymer can be effectively separated by increasing the elution pH, and the polymer is further reduced. According to the method disclosed by the invention, the purity of the fasuximab can be effectively improved, the polymer content is reduced, and the process is simple and easy to operate.
Owner:QILU PHARMA CO LTD
